Viewing Study NCT05871398



Ignite Creation Date: 2024-05-06 @ 7:02 PM
Last Modification Date: 2024-10-26 @ 2:59 PM
Study NCT ID: NCT05871398
Status: COMPLETED
Last Update Posted: 2023-06-01
First Post: 2023-05-02

Brief Title: The Efficacy of Potassium-competitive Acid Blocker in Patients With Laryngopharyngeal Reflux Disease
Sponsor: Pusan National University Hospital
Organization: Pusan National University Hospital

Study Overview

Official Title: The Efficacy of Potassium-competitive Acid Blocker P-CAB in Patients With Laryngopharyngeal Reflux Disease a Double- Blind Randomized Placebo-controlled Pilot Study
Status: COMPLETED
Status Verified Date: 2023-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: BackgroundAims Tegoprazan is a novel potassium-competitive acid blocker that has a fast onset of action and can control gastric pH for a prolonged period which could offer clinical benefit in acid-related disorders The investigators aimed to evaluate whether tegoprazan would be more effective in controlling symptoms than placebo in patients with laryngopharyngeal reflux disease LPRD Methods This double-blind randomized placebo-controlled trial randomly assigned 35 patients suffering LPRD symptom to two groups Tegoprazan50mg once daily and placebo The primary end point was complete resolution rate of LPRD symptoms after 8-week medication and the secondary endpoints were complete resolution rate of LPRD symptoms after 4-week medication change of reflux symptom index RSI and reflux finding score RFS from baseline at 4- and 8-week medication
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None